Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis

Restricted access

With the advent of widespread tumor genetic profiling, an increased number of mutations with unknown significance are being identified. Often, a glut of uninterpretable findings may confuse the clinician and provide little or inappropriate guidance in therapeutic decision-making. This report describes a method of protein modeling by in silico analysis (ie, using computer simulation) that is easily accessible to the practicing clinician without need for further laboratory analysis, which can potentially serve as a guide in therapeutic decisions based on poorly characterized tumor mutations. An example of this model is given wherein poorly characterized KIT, PDGFRB, and ERBB2 mutations were discovered in a patient with treatment-refractory metastatic transitional cell carcinoma of the renal pelvis. The KIT and PDGFRB mutations were predicted to be pathogenic using in silico analysis, whereas the ERBB2 mutation was predicted to be benign. Based on these findings, the patient was treated with pazopanib and achieved a partial response that lasted for 7.5 months. We propose that in silico analysis be explored as a potential means to further characterize genetic abnormalities found by tumor profiling assays, such as next-generation sequencing.

Correspondence: Andrew W. Hahn, BA, The University of Tennessee Health Science Center/West Cancer Center, 1588 Union Avenue, c/o Dr. Mike G. Martin, Memphis, TN 38104. E-mail: ahahn1@uthsc.edu
  • 1.

    RamanJDMesserJSielatyckiJAHollenbeakCS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int2011;107:10591064.

    • Search Google Scholar
    • Export Citation
  • 2.

    GallagherDJMilowskyMIBajorinDF. Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting. Cancer2008;113:12841293.

    • Search Google Scholar
    • Export Citation
  • 3.

    MorrisonCDLiuPWoloszynska-ReadA. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A2014;111:E672681.

    • Search Google Scholar
    • Export Citation
  • 4.

    RossJSWangKAl-RohilRN. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol2014;27:271280.

    • Search Google Scholar
    • Export Citation
  • 5.

    ChangFLiMM. Clinical application of amplicon-based next-generation sequencing in cancer. Cancer Genet2013;206:413419.

  • 6.

    TseCShoemakerARAdickesJ. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res2008;68:34213428.

  • 7.

    WallaceMDPfefferleADShenL. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics2012;192:385396.

    • Search Google Scholar
    • Export Citation
  • 8.

    PolyPhen-2: Prediction of Functional Effects of Human nsSNPs. Available at: http://genetics.bwh.harvard.edu/pph2/. Accessed September 9 2015.

    • Search Google Scholar
    • Export Citation
  • 9.

    GanjooKNVillalobosVMKamayaA. A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol2014;25:236240.

    • Search Google Scholar
    • Export Citation
  • 10.

    KwakCLeeSEJeongIGKuJH. Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology2006;68:5357.

    • Search Google Scholar
    • Export Citation
  • 11.

    DasanuCAOng-BacayACodreanuI. Newer developments in the therapeutics of the transitional cell carcinoma of renal pelvis. J Oncol Pharm Pract2012;18:97103.

    • Search Google Scholar
    • Export Citation
  • 12.

    SternbergCNYagodaAScherHI. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer1989;64:24482458.

    • Search Google Scholar
    • Export Citation
  • 13.

    RossJSWangKGayL. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies. JAMA Oncol2015;1:4049.

    • Search Google Scholar
    • Export Citation
  • 14.

    BaoRHuangLAndradeJ. Review of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing. Cancer Inform2014;13(Suppl 2):6782.

    • Search Google Scholar
    • Export Citation
  • 15.

    YadavSSLiJLaveryHJ. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment. Urol Oncol2015;33:267.e113.

    • Search Google Scholar
    • Export Citation
  • 16.

    Precipio DiagnosticsSmartGen. Available at: http://www.precipiodx.com/Smartgen.html#sthash.u6OFvI6n.dpbs. Accessed September 9 2015.

  • 17.

    Comprehensive molecular characterization of urothelial bladder carcinoma. Nature2014;507:315322.

  • 18.

    AdzhubeiIASchmidtSPeshkinL. A method and server for predicting damaging missense mutations. Nat Methods2010;7:248249.

  • 19.

    TavtigianSVGreenblattMSLesueurFByrnesGB. In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat2008;29:13271336.

    • Search Google Scholar
    • Export Citation
  • 20.

    ChanPADuraisamySMillerPJ. Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Human Mutat2007;28:683693.

    • Search Google Scholar
    • Export Citation
  • 21.

    ChaoECVelasquezJLWitherspoonMS. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Human Mutat2008;29:852860.

    • Search Google Scholar
    • Export Citation
  • 22.

    SternbergCNDavisIDMardiakJ. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010;28:10611068.

    • Search Google Scholar
    • Export Citation
  • 23.

    PiliRQinRFlynnPJ. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer2013;11:477483.

    • Search Google Scholar
    • Export Citation
  • 24.

    NecchiAMarianiLZaffaroniN. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol2012;13:810816.

    • Search Google Scholar
    • Export Citation
  • 25.

    GerullisHEimerCEckeTH. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs2013;24:422425.

    • Search Google Scholar
    • Export Citation
  • 26.

    GallagherDJMilowskyMIGerstSR. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol2010;28:13731379.

    • Search Google Scholar
    • Export Citation
  • 27.

    PowlesTEderJPFineGD. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature2014;515:558562.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 99 91 10
PDF Downloads 28 23 2
EPUB Downloads 0 0 0